GSK CH is a large cap consumer health company, it is one of the largest 5 companies in consumer health. Operating across 6 different therapeutic areas, in a global capacity with local footprint across all continents. The innovation pipeline therefore can be expected to be broad in terms of quantity, value, and innovation types.
GSK CH’s Innovation Pipeline was evolving, moreso after a recent merger, and it was imperative to be able to see all the different performance measures in one place across all products launching over the next 5 years, the general layout of the challenge was that: The innovation pipeline therefore can be expected to be broad in terms of quantity, value, and innovation types.
Data integrity needed to be maintained, that included process setting, stakeholder management, and Data Quality Management automated process design and implementation.
Unified metrics and KPIs needed to be captured and reported across all governances of the organization.
Insights for prioritization and resource allocation needed to be automated for governance meetings and portfolio leadership.
The time from analysis to action was extravagant, each governance had its own practices that it wanted to stick to, and the data pipeline was full of inadequate steps that hinder data integrity. An automated solution was a dire need.
We worked with them on a five-step process, listed above, that allowed for the executives to take back 30% of their time while doubling their innovation growth margins. The outcome that they saw was a suite of analytics that allowed them to make data-driven decisions. Below is a quick tour of the three of the key features of the solution.